Recent research has unveiled a significant link between the genetic burden of depression and the activity of multiple sclerosis (MS), shedding light on how depression predisposition can impact disease outcomes. Published in the Annals of Neurology, the study marks the first to establish an association between an elevated cumulative genetic burden of depression and increased MS disease activity. While the correlation between depression and MS has been recognized in past epidemiological studies, the challenge of reverse causality has often clouded the relationship. By focusing on genetic factors, this study aimed to clarify whether genetic predispositions related to depression could influence MS outcomes independently of a depression diagnosis.
The investigation involved 3420 individuals with relapsing-onset MS across four studies from Canada, the United States, and Sweden, with a median follow-up period of 3 to 5 years. Utilizing a polygenic score (PGS) to quantify genetic predisposition for depression, the researchers sought to determine the impact of depression genetics on MS disease activity and disability progression. Genetic factors were prioritized due to their unchanging nature throughout an individual’s lifespan, offering a stable foundation to explore the link between depression genetics and MS outcomes, thereby mitigating concerns of reverse causation.
The study revealed compelling results, indicating that for each standard deviation increase in the depression PGS, the annual relapse rate in MS patients surged by 23%. Furthermore, in the US cohort, a higher depression PGS was associated with a 58% higher risk of defined relapses and a 51% increased risk of confirmed disability progression as measured by the Expanded Disability Status Scale (EDSS). Notably, mediation analyses suggested a direct effect of depression PGS on MS relapses and disability worsening in the US cohort, implying shared biological processes influencing both depression and MS outcomes. While these findings were not replicated in the Canadian cohort, further exploration of underlying mechanisms is warranted to assess the potential impact of antidepressant treatments on MS outcomes.
Despite the study’s valuable insights, the authors acknowledged certain limitations, such as the predominantly European genetic ancestry of over 90% of the cohort, which may restrict the generalizability of the results. They emphasized the necessity of future genetic studies incorporating individuals with MS from diverse ancestries to enhance the breadth of understanding. While the use of genetic data helped alleviate concerns of reverse causality, the study falls short of definitively establishing a causal relationship between depression genetics and MS outcomes.
In conclusion, the study underscores a significant association between a heightened genetic burden of depression and increased MS disease activity, offering a fresh perspective on the intricate interplay between depression predisposition and MS outcomes. By delving into the genetic underpinnings of depression, researchers have uncovered potential shared biological mechanisms influencing both conditions, paving the way for targeted interventions and personalized treatment strategies that could positively impact MS prognosis in individuals with a genetic predisposition for depression.
Takeaways:
– Elevated genetic burden of depression correlates with increased MS disease activity and disability progression.
– Genetic predisposition for depression, as quantified by a polygenic score, may influence MS outcomes independently of a depression diagnosis.
– Shared biological processes between depression and MS suggest potential targets for intervention and personalized care strategies.
– Further research is needed to explore the impact of antidepressant treatments on MS outcomes in individuals with a genetic predisposition for depression.
Tags: bispecifics
Read more on ajmc.com